Pharmaceutical & Life Sciences News

Fresenius Plunges by Most Ever After Another Profit Warning (3)

Dec. 7, 2018, 2:45 PM

Fresenius SE plunged by a record amount after the German health-care company abandoned its financial goals through 2020, its second profit warning in as many months.

The conglomerate plans to boost investments in “infrastructure and capabilities” at a time of sluggish growth in its hospital division and mounting challenges for its intravenous drugs unit, Kabi. The kidney-dialysis subsidiary is struggling, too, as customers shift to at-home treatments. Shares fell as much as 19 percent to the lowest level since October 2014.

“Investors are likely to be concerned about the growth rate at all three of Fresenius’s major divisions,” Ian Douglas-Pennant,...

To read the full article log in. To learn more about a subscription click here.